LIPO
Lipella Pharmaceuticals Inc.NASDAQHealthcare$0.02-0.45%ClosedMarket Cap: $101,658
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
0.07
P/S
0.59
EV/EBITDA
0.28
DCF Value
$-9.85
FCF Yield
-2312584.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1954.7%
Operating Margin
-3115.2%
Net Margin
-3069.0%
ROE
-208.4%
ROA
-226.8%
ROIC
-308.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | -Infinity% | $-1.3M | $-1.3M | $-0.28 | — |
| Q2 2025 | $0.00 | -Infinity% | $-1.4M | $-1.3M | $-0.31 | — |
| Q1 2025 | $0.00 | -Infinity% | $-1.3M | $-1.3M | $-0.64 | — |
| Q4 2024 | $173.7K | -511.7% | $-1.5M | $-1.4M | $-1.37 | — |
| FY 2024 | $536.4K | -573.7% | $-5.1M | $-5.0M | $-4.79 | — |
| Q3 2024 | $0.00 | -Infinity% | $-1.5M | $-1.4M | $-1.29 | — |
| Q2 2024 | $0.00 | -Infinity% | $-952.2K | $-938.1K | $-0.99 | — |
| Q1 2024 | $0.00 | -Infinity% | $-1.2M | $-1.2M | $-1.31 | — |
| Q4 2023 | $449.6K | -1.0% | $-729.6K | $-688.9K | $-0.84 | — |
| FY 2023 | $449.6K | -575.9% | $-4.7M | $-4.6M | $-6.16 | — |
| Q3 2023 | $104.1K | -700.8% | $-1.4M | $-1.3M | $-1.84 | — |
| Q2 2023 | $0.00 | -Infinity% | $-1.6M | $-1.5M | $-2.16 | — |